Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

NCT00255008 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

121

Enrollment

INDUSTRY

Sponsor class

Stopped Slow enrollment

Conditions

Hepatitis C, Chronic

Interventions

BIOLOGICAL: peginterferon alfa-2b
DRUG: ribavirin
BIOLOGICAL: peginterferon alfa-2b
DRUG: ribavirin

Sponsor

Merck Sharp & Dohme LLC